Gastroesophageal Reflux Treatment in Scleroderma

Phase 1 SSc patients who fit all inclusion and exclusion criteria will be eligible to phase 1 study for evaluation the prevalence of omeprazole resistant-GERD

Inclusion criteria

• SSc patients aged between 18 and 65 years.
• Clinically diagnosed as GERD and GERD-questionnaire score >3
• Must not receive any proton pump inhibitor (PPI) or prokinetic drug within 2 weeks before baseline evaluation

Exclusion criteria

• Pregnancy or lactation
• Previous history of gastroesophageal surgery or endoscopic therapy due to severe erosive esophagitis
• Present of Barrett's esophagus
• Bedridden and confined to no self-care
• Evidence of active malignant disease
• Present of uncontrolled or severe medical problems such as asthma, angina, hepatic or renal diseases
• Present of active infection that needs systemic antibiotic
• Allergic history of omeprazole
• Receiving prohibit co-medications that may have drug interaction or attenuate GERD symptoms such as tetracycline, ferrous salt, digoxin, isoniacid, oral bisphosphonate

Phase 2 randomized parallel study SSc patients who fit all inclusion and exclusion criteria will be eligible to phase 2 study.

Inclusion criteria

• SSc patients who completed the phase 1 study.
• The subjects were defined as PPI-resistance.
• The subject must be willing to continue phase 2 study.

Exclusion criteria

• Pregnancy
• Present of uncontrolled or severe medical problems
• Present of active infection
• Allergic history of alginic acid or domperidone
• Receiving prohibit co-medications that may have drug interaction or attenuate GERD symptoms such as tetracycline, ferrous salt, digoxin, isoniacid, oral bisphosphonate
• Chewing difficulty